Straits Times Index
3,300.04 -3.15 (-0.10%) S&P 500
5,195.11 +14.37 (+0.28%) Dow
38,938.66 +86.39 (+0.22%) Nasdaq
16,379.30 +30.05 (+0.18%) Bitcoin USD
63,839.93 +508.81 (+0.80%) CMC Crypto 200
1,323.88 -41.25 (-3.02%)
ABIONYX Pharma SA (ABNX.PA)
| Previous close | 1.0620 |
| Open | 1.0400 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 1.0240 - 1.0560 |
| 52-week range | 0.9100 - 2.1600 |
| Volume | |
| Avg. volume | 54,416 |
| Market cap | 33.817M |
| Beta (5Y monthly) | -0.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2023
TOULOUSE, France & LAKELAND, Mich., May 02, 2024--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces that it has filed with the "Autorité des Marchés Financiers" (AMF) its Universal Registration Document for the year ended December 31, 2023, dated April 30, 2024.
- Business Wire
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
PARIS, April 10, 2024--Regulatory News: ABIONYX Pharma (Paris:ABNX)
- Business Wire
ABIONYX Pharma - Bpifrance Supports the Development of CER-001 in Ophthalmology With a Nearly €1 Million Non-dilutive Innovation Grant
TOULOUSE, France & LAKELAND, Mich., March 14, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces a nearly €1 million innovation grant from Bpifrance. The aim of this grant is to support the development of drug candidate CER-001 in the treatment of a severe indication in ophthalmology.
